Fig. 3

FLT3L-induced CD44^high CD8 T cells elicit tumor immunity against B16ova tumors. A C57BL/6 mice were inoculated with B16-OVA cells subcutaneously. Six days later, mice were injected intravenously through the retroorbital sinus with 2 × 10⁶ CD44^high CD8 T cells that were sorted from control naïve or FLT3L-treated OT-1 mice. Eighteen days after adoptive T cell implantation, mice were euthanized and tumor tissues and drained lymph nodes were harvested for flow cytometry analysis. B Tumor growth curve following the described treatment protocol. C, D The frequencies of OVA-specific CD8 T cells in the tumor-draining lymph node (C) and tumor (D). E The frequencies of IFNγ⁺ CD8 T cells in the tumors F. The frequencies of CD25⁺ CD8 T cells in the tumors. N = 5 mice per group. Data is represented by mean ± SEM. p values were calculated by ordinary one-way ANOVA with the Tukey–Kramer multiple comparison test, and p < 0.05 is considered statistically significant. *, **, ***, and ****Indicate p values less than 0.05, 0.01, 0.001, and 0.0001, respectively